Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adult acne

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Adult acne. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-001753-26 Sponsor Protocol Number: DC0984LE401 Start Date*: 2013-07-25
    Sponsor Name:Pierre Fabre Dermo-cosmétique
    Full Title: Clinical and biophysics evaluation of the cutaneous modifications following the local use of a lotion containing 0,1 % of trétinoïne.
    Medical condition: Acne
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    18.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    18.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    18.0 10040785 - Skin and subcutaneous tissue disorders 10040798 Skin appendage conditions HLGT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000063-16 Sponsor Protocol Number: RD.03.SPR.109807 Start Date*: 2016-06-10
    Sponsor Name:Galderma R&D SNC
    Full Title: Efficacy and safety of CD5024 1% in acne vulgaris
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001392-22 Sponsor Protocol Number: RC16_0467 Start Date*: 2017-09-27
    Sponsor Name:CHU de Nantes
    Full Title: Randomized double-blind study on the benefit of spironolactone for treating acne of adult woman
    Medical condition: Acne vulgaris of adult woman
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002057-65 Sponsor Protocol Number: RD.03.SPR.40161E Start Date*: 2011-09-01
    Sponsor Name:Galderma R&D SNC
    Full Title: Effect of CD08100/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4 week treatment period.
    Medical condition: Erythematotelangiectatic rosacea
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003796-58 Sponsor Protocol Number: NAC-GED-0507-ACN-02-17 Start Date*: 2017-12-13
    Sponsor Name:PPM SERVICES S.A.
    Full Title: AN OPEN LABEL CLINICAL STUDY TO EVALUATE THE LONG-TERM DERMAL SAFETY PROFILE OF 12-WEEKS TOPICAL ADMINISTRATION OF N-ACETYL-GED-0507-34-LEVO GEL 5% IN PATIENTS WITH FACIAL ACNE
    Medical condition: FACIAL ACNE
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005244-17 Sponsor Protocol Number: GED-0507-ACN-01-14 Start Date*: 2015-09-28
    Sponsor Name:PPM SERVICES S.A.
    Full Title: AN OPEN LABEL CLINICAL STUDY TO EVALUATE THE LONG-TERM DERMAL SAFETY PROFILE OF 12-WEEKS TOPICAL ADMINISTRATION OF TWO DIFFERENT DOSES OF N-ACETYL-GED-0507-34-LEVO GEL IN PATIENTS WITH MILD TO MODE...
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003707-40 Sponsor Protocol Number: RD.03.SPR.40031 Start Date*: 2007-01-09
    Sponsor Name:Galderma Research and Development SNC
    Full Title: Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea.
    Medical condition: Erythemato-Telangiectatic Rosacea (ETR)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039218 Rosacea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004998-83 Sponsor Protocol Number: MUS92579_2057_1 Start Date*: 2012-04-04
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A Double-Blind, Randomized, Dose Selection Vehicle–Controlled Multicenter Clinical Study for Evaluation of the Safety, Tolerability, Efficacy, and Pharmacokinetics of topical Neramexane in Subjects...
    Medical condition: Moderate to severe acne
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003630-33 Sponsor Protocol Number: ERGO45359 Start Date*: 2019-01-23
    Sponsor Name:University of Southampton
    Full Title: Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe p...
    Medical condition: Acne of sufficient severity to warrant treatment with oral antibiotics.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-021150-19 Sponsor Protocol Number: AMC-DOMIRO-40100 Start Date*: 2010-10-05
    Sponsor Name:Academical medical Center, Department of dermatology
    Full Title: Doxycycline versus minocycline in the treatment of rosacea: a randomised controlled trial.
    Medical condition: Patients with moderate to severe, papulopustular rosacea.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013111-35 Sponsor Protocol Number: RD.03.SPR.40099E Start Date*: 2009-12-23
    Sponsor Name:Galderma R&D SNC
    Full Title: EFFECT OF CD08514 VERSUS PLACEBO, IN PATIENTS PRESENTING WITH TYPE 1 ROSACEA, OVER AN 8-WEEK TREATMENT
    Medical condition: Moderate to severe erythematotelangiectactic rosacea (ETR)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039218 Rosacea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002058-30 Sponsor Protocol Number: RD.03.SPR.40162E Start Date*: 2011-11-24
    Sponsor Name:Galderma R&D SNC
    Full Title: Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6-week treatment period.
    Medical condition: Papulopustular rosacea
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005297-48 Sponsor Protocol Number: HUM 06-0023 Start Date*: 2007-03-20
    Sponsor Name:University of Copenhagen, Roskilde, Department of Dermatology
    Full Title: Adalimumab s.c. for the treatment of patients with hidradenitis suppurativa – clinical efficacy, safety and tolerability - SOPHISTICATE
    Medical condition: Patients with hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000540-33 Sponsor Protocol Number: GED-0507-ACN-01-16 Start Date*: 2016-06-02
    Sponsor Name:PPM Services S.A.
    Full Title: A double-blind, randomised, placebo-controlled clinical study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 1 and 2%, applied once daily for 12 weeks in patients with mild t...
    Medical condition: facial acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-000475-25 Sponsor Protocol Number: SPON489-07 Start Date*: 2009-11-10
    Sponsor Name:Cardiff University
    Full Title: Randomised, controlled, double-blind, parallel group clinical trial evaluating the efficacies and safety of methyl-aminolevulinate photodynamic therapy and intense pulsed light, administered as pl...
    Medical condition: Mild to moderate acne vulgaris in adult patients.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000049-42 Sponsor Protocol Number: UNI50007-201 Start Date*: 2021-09-16
    Sponsor Name:Zealand University Hospital (Universitetshospital Sjælland)
    Full Title: Orismilast for the treatment of mild to severe hidradenitis suppurativa; A phase 2, open-label, proof of concept trial comparing the response to an oral tablet formulation of orismilast in adult pa...
    Medical condition: Hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004108-33 Sponsor Protocol Number: M20-262 Start Date*: 2022-03-09
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Subjects with Moderate to Severe Hidradenitis Suppurat...
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003672-40 Sponsor Protocol Number: 1368-0052 Start Date*: 2021-03-02
    Sponsor Name:Boehringer Ingelheim France
    Full Title: Randomized, double-blind, placebo-controlled, study of spesolimab in patients with moderate or severe hidradenitis suppurativa
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) CZ (Completed) BE (Completed) NL (Completed) DE (Completed) GR (Prematurely Ended) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005587-55 Sponsor Protocol Number: 1368-0067 Start Date*: 2021-06-03
    Sponsor Name:Boehringer Ingelheim France
    Full Title: An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) DE (Completed) NO (Completed) CZ (Completed) NL (Completed) BE (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002063-26 Sponsor Protocol Number: CAIN457M2301 Start Date*: 2019-01-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient...
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) PT (Completed) HU (Completed) SK (Completed) CZ (Completed) BE (Completed) GR (Completed) AT (Completed) SE (Completed) ES (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 22:37:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA